1 October 2015 - Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market Juvederm Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. Juvederm Ultra XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

"As the leader in medical aesthetics, Allergan is committed to continued research and development in this area," said Philippe Schaison, Executive Vice President & President, Allergan Medical. "Providing physicians and patients with premium products that allow them to achieve the aesthetic results they want is always our goal. Understanding that the desire with lip augmentation is to achieve a natural-looking and lasting result, we continued our research of Juvederm Ultra XC for the lips. With this approval, Juvederm Ultra XC is now the only filler that is approved to last up to one year in the lips while providing natural-looking results."

For more details, go to: http://www.allergan.com/news/news/thomson-reuters/u-s-fda-approves-juvederm-ultra-xc-for-use-in-lips